A citation-based method for searching scientific literature

Peter de Bruijn, Stefan Sleijfer, Mei-Ho Lam, Ron H J Mathijssen, Erik A C Wiemer, Walter J Loos. J Pharm Biomed Anal 2010
Times Cited: 38







List of co-cited articles
210 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Patton Minkin, Ming Zhao, Zhaoyuan Chen, Jan Ouwerkerk, Hans Gelderblom, Sharyn D Baker. J Chromatogr B Analyt Technol Biomed Life Sci 2008
47
42

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Marie-Christine Etienne-Grimaldi, Nicole Renée, Hassan Izzedine, Gérard Milano. J Chromatogr B Analyt Technol Biomed Life Sci 2009
30
50

Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.
R Honeywell, K Yarzadah, E Giovannetti, N Losekoot, E F Smit, M Walraven, J S W Lind, C Tibaldi, H M Verheul, G J Peters. J Chromatogr B Analyt Technol Biomed Life Sci 2010
66
39


Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
A Haouala, B Zanolari, B Rochat, M Montemurro, K Zaman, M A Duchosal, H B Ris, S Leyvraz, N Widmer, L A Decosterd. J Chromatogr B Analyt Technol Biomed Life Sci 2009
139
36


Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
Stéphane Bouchet, Emmanuelle Chauzit, Dominique Ducint, Nadège Castaing, Mireille Canal-Raffin, Nicholas Moore, Karine Titier, Mathieu Molimard. Clin Chim Acta 2011
119
36

Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
Benoit Blanchet, Carole Saboureau, Anne Sophie Benichou, Bertrand Billemont, Fabrice Taieb, Stanislas Ropert, Alain Dauphin, François Goldwasser, Michel Tod. Clin Chim Acta 2009
39
34


Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
Sandrine Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, Stéphanie Lozahic, Nathalie Lassau, Carlo Bello, Samuel Deprimo, Nicoletta Brega, Giorgio Massimini,[...]. J Clin Oncol 2006
945
28

Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma.
Lutz Götze, Axel Hegele, Stephan Klaus Metzelder, Harald Renz, Wolfgang Andreas Nockher. Clin Chim Acta 2012
67
28



A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
Nielka P van Erp, Djoeke de Wit, Henk-Jan Guchelaar, Hans Gelderblom, Trees J Hessing, Jan den Hartigh. J Chromatogr B Analyt Technol Biomed Life Sci 2013
57
28


Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Brett E Houk, Carlo L Bello, Bill Poland, Lee S Rosen, George D Demetri, Robert J Motzer. Cancer Chemother Pharmacol 2010
364
26

An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.
L Couchman, M Birch, R Ireland, A Corrigan, S Wickramasinghe, D Josephs, J Spicer, R J Flanagan. Anal Bioanal Chem 2012
53
26

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Vicki L Goodman, Edwin P Rock, Ramzi Dagher, Roshni P Ramchandani, Sophia Abraham, Jogarao V S Gobburu, Brian P Booth, S Leigh Verbois, David E Morse, Cheng Yi Liang,[...]. Clin Cancer Res 2007
365
23

Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies.
Rajneet K Oberoi, Rajendar K Mittapalli, James Fisher, William F Elmquist. Chromatographia 2013
20
45


Molecular basis for sunitinib efficacy and future clinical development.
Sandrine Faivre, George Demetri, William Sargent, Eric Raymond. Nat Rev Drug Discov 2007
516
21

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
Nienke A G Lankheet, Christian U Blank, Henk Mallo, Sandra Adriaansz, Hilde Rosing, Jan H M Schellens, Alwin D R Huitema, Jos H Beijnen. J Anal Toxicol 2011
25
32

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Dirk B Mendel, A Douglas Laird, Xiaohua Xin, Sharianne G Louie, James G Christensen, Guangmin Li, Randall E Schreck, Tinya J Abrams, Theresa J Ngai, Leslie B Lee,[...]. Clin Cancer Res 2003
18


A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Carolyn D Britten, Fairooz Kabbinavar, J Randolph Hecht, Carlo L Bello, Jim Li, Charles Baum, Dennis Slamon. Cancer Chemother Pharmacol 2008
118
15

New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
Silvia De Francia, Antonio D'Avolio, Francesca De Martino, Elisa Pirro, Lorena Baietto, Marco Siccardi, Marco Simiele, Silvia Racca, Giuseppe Saglio, Francesco Di Carlo,[...]. J Chromatogr B Analyt Technol Biomed Life Sci 2009
73
15

Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
Milly E de Jonge, Alwin D R Huitema, Jan H M Schellens, Sjoerd Rodenhuis, Jos H Beijnen. Clin Pharmacokinet 2005
80
15



Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
George D Demetri, Allan T van Oosterom, Christopher R Garrett, Martin E Blackstein, Manisha H Shah, Jaap Verweij, Grant McArthur, Ian R Judson, Michael C Heinrich, Jeffrey A Morgan,[...]. Lancet 2006
13

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Negrier, Cezary Szczylik, Sindy T Kim,[...]. N Engl J Med 2007
13

Sunitinib maleate.
Michael Atkins, Carole A Jones, Peter Kirkpatrick. Nat Rev Drug Discov 2006
107
13

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.
Carlo L Bello, Laurie Sherman, Jihao Zhou, Lev Verkh, John Smeraglia, Janessa Mount, Karen J Klamerus. Anticancer Drugs 2006
113
13

Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
Bill Speed, Hai-Zhi Bu, William F Pool, Geoffrey W Peng, Ellen Y Wu, Shem Patyna, Carlo Bello, Ping Kang. Drug Metab Dispos 2012
71
13

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
N A G Lankheet, J S L Kloth, C G M Gadellaa-van Hooijdonk, G A Cirkel, R H J Mathijssen, M P J K Lolkema, J H M Schellens, E E Voest, S Sleijfer, M J A de Jonge,[...]. Br J Cancer 2014
71
13

Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Huixin Yu, Neeltje Steeghs, Cynthia M Nijenhuis, Jan H M Schellens, Jos H Beijnen, Alwin D R Huitema. Clin Pharmacokinet 2014
155
13

Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Nienke A G Lankheet, Lotte M Knapen, Jan H M Schellens, Jos H Beijnen, Neeltje Steeghs, Alwin D R Huitema. Ther Drug Monit 2014
70
13

Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Maikel Herbrink, Niels de Vries, Hilde Rosing, Alwin D R Huitema, Bastiaan Nuijen, Jan H M Schellens, Jos H Beijnen. Ther Drug Monit 2016
33
15


A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Walter Fiedler, Hubert Serve, Hartmut Döhner, Michael Schwittay, Oliver G Ottmann, Anne-Marie O'Farrell, Carlo L Bello, Randy Allred, William C Manning, Julie M Cherrington,[...]. Blood 2005
417
10



Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Stephane Picard, Karine Titier, Gabriel Etienne, Emmanuelle Teilhet, Dominique Ducint, Marie-Agnes Bernard, Regis Lassalle, Gerald Marit, Josy Reiffers, Bernard Begaud,[...]. Blood 2007
451
10

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
Joshua O Haznedar, Shem Patyna, Carlo L Bello, Geoffrey W Peng, William Speed, Xiaoming Yu, Qingling Zhang, Juthamas Sukbuntherng, David J Sweeny, Lida Antonian,[...]. Cancer Chemother Pharmacol 2009
54
10

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
Richard A Larson, Brian J Druker, Francois Guilhot, Stephen G O'Brien, Gilles J Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang. Blood 2008
463
10


Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
Rolf W Sparidans, Tahani T A Ahmed, Eline W Muilwijk, Marieke E B Welzen, Jan H M Schellens, Jos H Beijnen. J Chromatogr B Analyt Technol Biomed Life Sci 2012
14
28

Clinical pharmacokinetics of tyrosine kinase inhibitors.
Nielka P van Erp, Hans Gelderblom, Henk-Jan Guchelaar. Cancer Treat Rev 2009
291
10

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Nicolas Widmer, Christophe Bardin, Etienne Chatelut, Angelo Paci, Jos Beijnen, Dominique Levêque, Gareth Veal, Alain Astier. Eur J Cancer 2014
197
10

A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the European Medicines Agency guidelines.
Iris Garrido-Cano, Aurelio García-García, Juan Peris-Vicente, Enrique Ochoa-Aranda, Josep Esteve-Romero. Talanta 2015
18
22


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.